Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne

BioWest Therapeutics

Status and phase: Completed; Phase 2

Conditions: Acne; Acne Vulgaris; Propionibacterium Acnes

Treatments: Drug: MBI 226 Acne Solutions

Study type: Interventional

Funder types: Industry

Identifiers

NCT00211497

A99005

Details and patient eligibility

About

This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with facial acne vulgaris.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females 12 years and older
• Presence of inflammatory and non-inflammatory lesions

Exclusion criteria

• Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.)
• Active facial cysts or any nodulocystic lesions

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind